Open Access4CPS-069 Economic impact of off-label use of dalbavancin for treatment of infectious endocarditis and bloodstream infections caused by grampositive bacteria
Author(s) -
SE de Jesus,
S Sadyrbaeva,
Carmen Hidalgo-Tenorio,
Alberto Jiménez-Morales,
Juan Pasquau
Publication year - 2018
Publication title -
section 4: clinical pharmacy services
Language(s) - English
Resource type - Conference proceedings
DOI - 10.1136/ejhpharm-2018-eahpconf.160
Subject(s) - dalbavancin , medicine , daptomycin , endocarditis , dosing , bacteremia , antibiotics , enterococcus faecalis , enterococcus , staphylococcus aureus , vancomycin , microbiology and biotechnology , biology , bacteria , genetics
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom